The probability of receiving a kidney transplantation in end-stage kidney disease patients who are treated with haemodiafiltration or haemodialysis: a pooled individual participant data from four randomised controlled trials

Robin W. M. Vernooij 1,2, Way Law 1,3, Sanne A. E. Peters 2,4,5, Bernard Canaud 6,7, Andrew Davenport 8, Muriel P. C. Grooteman 9, Fatih Kircelli 10, Francesco Locatelli 11, Francisco Maduell 12, Marion Morena 13, Menso J. Nubé 9, Ercan Ok 10, Ferran Torres 14,15, Mark Woodward 4,5,16, Peter J. Blankestijn 1*, Michiel L. Bots 2 on behalf of the HDF Pooling project investigators

Abstract

Background: Due to a critical shortage of available kidney grafts, most patients with Stage 5 Chronic Kidney Disease (CKD5) require bridging dialysis support. It remains unclear whether treatment by different dialysis modalities changes the selection and/or preparation of a potential transplant candidate. Therefore, we assessed whether the likelihood of receiving kidney transplant (both living or deceased kidney donors) differs between haemodialysis (HD) and online haemodiafiltration (HDF) in patients with CKD5D.

Methods: Individual participant data from four randomised controlled trials comparing online HDF with HD were used. Information on kidney transplant was obtained during follow-up. The likelihood of receiving a kidney transplant was compared between HD and HDF, and evaluated across different subgroups: age, sex, diabetes, history of cardiovascular disease, albumin, dialysis vintage, fistula, and level of convection volume standardized to body surface area. Hazard ratios (HRs), with corresponding 95% confidence intervals (95% CI), comparing the effect of online HDF versus HD on the likelihood of receiving a kidney transplant, were estimated using Cox proportional hazards models with a random effect for study.

(Continued on next page)
Introduction
Kidney transplantation is the treatment of choice for patients with Stage 5 Chronic Kidney Disease (CKD5). Yet, due to an aging population and an increased prevalence of CKD5 in patients with diabetes and hypertension [1], a critical shortage exists of available kidney grafts for transplantation [2, 3]. Consequently, most patients with CKD5 require bridging dialysis support (CKD5D). The role of the different dialysis modalities, i.e. haemodialysis (HD), peritoneal dialysis (PD), or haemodiafiltration (HDF), with respect to the selection and/or preparation of receiving kidney transplantation has been the topic of persistent discussion [4–6]. While most previous research regarding the selection and/or preparation of kidney transplantation candidates focused on the comparison between PD and HD [7–9], limited evidence is available regarding the comparison of HDF and HD [10, 11]. While the convection volume in standard HD approximates 10 L/session, in online post-dilution HDF the convection volume may amount to 23 L/1.73m²/session. Online HDF has been associated with a lower all-cause and cardiovascular mortality risk when compared with HD, especially for the patients receiving the highest delivered convection volume [12]. Yet, so far it is unclear whether HDF influences the eligibility and preparation time for receiving a renal transplant in these patients.

The choice of dialysis modality might potentially affect the selection or preparation of potential kidney transplant candidates due to several differences between dialysis modalities. For example, several aspects of immune function and cytokine production, such as (micro) inflammation and oxidative stress [7, 13], the hemodynamic treatment tolerance [11], and risk of intradialytic hemodynamic instability, and hence, injury to vital organs, including the heart and brain, vary between dialysis modalities [7, 14]. Additionally, HD membranes might increase free radical production by activating complement factors, phagocytes, and leucocytes [14, 15]. At the same time, patients might have been selected for a specific dialysis modality due to better prognostic factors (e.g. age or comorbidities) that can also affect the likelihood of receiving a kidney transplantation. Therefore, the aim of our study was to examine, in a pooled individual patient data analysis of four randomised controlled trials, first, whether the likelihood of receiving transplantation differs between HDF and HD, and second, whether the probability of receiving a kidney transplantation differed according to patient-, disease-, or other treatment-related characteristics.

Methods
Study design and study populations
A pooled individual participant data (IPD) meta-analysis was undertaken using data from four large multicentre randomised controlled trials (RCTs) comparing online HDF versus HD in adult patients with CKD5 receiving chronic HD [12]. All methods carried out and reported in accordance with relevant guidelines [16, 17]. Detailed description of the study designs, including eligibility criteria and treatment procedures, are provided elsewhere [18–21]. Briefly, the CONTRAST study included 714 patients treated by HD for ≥2 months in dialysis centres in the Netherlands, Canada, and Norway. A suggested target convection volume of 6 L/hour, i.e. generally 24 L/per session, was proposed [18]. The ESHOL study included 906 patients treated by HD for ≥3 months in Spain, with a minimum of 18 L/session of convection volume for the patients treated with online HDF [20]. The French HDF study included 391 patients, aged ≥65 years, treated by HD for >1 month, with no target online HDF convection volume specified [21]. The Turkish HDF study, including 782 patients without a specification of HD vintage, with a minimum target of 15 L/session convection volume for online HDF treatments [19]. In all studies patients were 1:1 randomised to either continuation of HD or online HDF, generally in a thrice weekly treatment schedule. In the CONTRAST study, patients in the control group were dialysed using low flux membranes, in the other three studies high flux membranes were used.
Study endpoints and follow-up
The primary outcome differed across studies: from all-cause mortality [18, 20], a composite outcome of all-cause mortality and nonfatal cardiovascular events [19], to intradialytic tolerance [21]. Secondary outcomes collected were cardiovascular mortality, infection mortality, and sudden death. The outcome of interest for this study is kidney transplant, for which information was collected in all studies during follow-up.

Statistical analysis
A similar statistical approach as the original IPD meta-analysis has been followed [12]. Hazard ratios (HRs), with corresponding 95% confidence intervals (95% CI), comparing the effect of online HDF versus HD on the suitability of kidney transplant candidates were estimated using Cox proportional hazards models with a random effect for study. Further analyses were conducted to evaluate whether this differed between subgroups on age (<65 vs. ≥65 years), sex, history of diabetes, history of CVD, albumin levels (<4 vs. ≥4 g/dL), dialysis vintage (<30 vs. ≥30 months), and mode of vascular access (arteriovenous fistula vs other). We used multiplicative interaction terms to explore whether differences in effect were present across subgroups. Additionally, study-specific results were computed for the CONTRAST and ESHOL studies; the other trials had too few patients to be able to obtain precise estimates. The dose-response association between online HDF and kidney transplantation was examined by precise estimates. The dose-response association between other trials had too few patients to be able to obtain

Results
Of the 2793 patients included, 355 (12.7%) underwent a kidney transplantation during a median follow-up of 2.5 years (Q1-Q3: 1.9–3.0 years). In the CONTRAST and ESHOL study, respectively, 21% (n = 151) and 20% (n = 180) of the patients included received a kidney transplant during follow-up, but in the French and Turkish studies these percentages were much smaller (n = 7 and n = 17, respectively, both 2%) (Appendix 1).

Patients who received a kidney transplant during follow-up were, on average, younger and had fewer comorbidities compared with those patients who did not receive a kidney transplant, but no differences by sex were found (Table 1). Patients who received a kidney transplant had significantly less dialysis vintage and more arteriovenous fistula access compared with patients who did not receive a kidney transplant. Albumin, haemoglobin, and pre-dialysis serum creatinine were greater, while C-reactive protein was lower, for those patients who received a transplant. There were no apparent differences in baseline characteristics, comorbidities, or laboratory measurements between the HD and the HDF study treatment arm for those patients who underwent a kidney transplantation.

The patients who received online HDF did not have a different likelihood of receiving a kidney transplantation compared with the patients receiving HD (HR: 1.07, 95%CI: 0.86–1.33) (Table 2). When adjusted for age, sex, diabetes, cardiovascular history, albumin, and creatinine, this finding remained similar (HR: 1.15, 95%CI: 0.92–1.44). This was consistent across all studies (Appendix 2). No evidence was found for a differential effect of online HDF compared to HD in subgroup of patients differing in sex, age, diabetes, CVD history, albumin, dialysis vintage, and vascular access for the likelihood of receiving kidney transplantation.

When compared to HD, the HRs by increasing delivered convection volume (<19, 19–23, and ≥23 l per 1.73 m² BSA per session) were 1.15 (0.82–1.61), 1.02 (0.75–1.41) and 1.06 (0.80–1.40), respectively (Table 3). The crude analyses and analyses adjusted for age, albumin, creatinine, history of CVD, and history of diabetes, give similar results.

Discussion
In this pooled IPD analysis including four RCTs, we identified no differences between pre-transplantation treatment with HD compared with pre-transplantation HDF in the likelihood of receiving kidney transplant in patients with CKD5D. There was no evidence to suggest that this finding differed across subgroups of patients, nor did the delivered convection volume per sessions influence this finding.

Due to an international shortage of available kidney grafts, many patients with CKD5D in clinical practice will have to undergo bridging dialysis support. Given that the underlying physiology of the different forms of dialysis varies, i.e. where HD mainly relies on diffusion, HDF consists of both diffusion and convection and is more efficient in removing middle molecules [22], this might have resulted in differences which could have affected patient suitability for kidney transplantation. Similarly, the survival benefit of HDF, i.e. a lower all-cause and cardiovascular mortality [12, 23–25], might also potentially contribute to differences selection and/or preparation of kidney transplant candidates. Patients
treated with HDF have a better preservation of left ventricle function [24, 26], and less intradialytic hypertensive episodes [11, 20, 27], which might preclude or defer patients from receiving a kidney transplantation. Consequently, taking these reasons into account, one could hypothesise that pre-transplantation treatment with HDF might make EKSD patients more suitable for a kidney transplantation. However, in this study, due to randomisation, we were able to exclude measured and unmeasured confounding by indication on better prognostic factors (e.g. age and comorbidities) that affect the likelihood of receiving a kidney transplantation. At the same time, there is no hypothesis that major determinants of transplant candidate selection, such as donor specific antibodies or human leukocyte antigens (HLA) matching, will be affected by the specific dialysis modality. Therefore, we conclude that the decision-making of patient suitability for kidney transplant does not depend on the specific choice of dialysis modality.

In the French and the Turkish study, both part of the IPD meta-analysis, the proportion of patients receiving a kidney transplantation during follow-up was very low (2%) and therefore not included in our main analysis. This might be explained by several factors related to either local healthcare policy, cultural differences, or patient characteristics and personal intention. For example, although the rate of kidney transplant per million inhabitants is higher in Turkey than the rest of Europe, this is largely caused by a higher rate of living kidney transplants [28]. Given that the majority of kidney transplants in our study come from deceased donors and not living donors, this might explain the low transplantation rate in this study. On the other hand, the average age of the patients included in the French study was 76 years due to advanced age being a selection criterion [21], compared with the other studies (mean age: 64.1 years, 65.4 years, and 56.5 years in, respectively, CONTRAST, ESHOL, and Turkish study) [18–20], meaning that most transplant candidates were excluded. Consequently, the French and Turkish studies were underpowered to analyse the likelihood of receiving a kidney transplant. The criteria of kidney transplantation were according to the local policies regarding transplantation, and the patients included in the French and Turkish studies were underpowered to analyse the likelihood of receiving a kidney transplant.

### Table 1. Baseline characteristics of study participants by treatment allocation and transplantation during follow-up

|                    | No transplantation | Transplantation | p-value** | No transplantation | Transplantation | p-value** | p-value*** |
|--------------------|--------------------|-----------------|-----------|--------------------|-----------------|-----------|------------|
| N                  | 654                | 152             |           | 635                | 179             |           |            |
| Age (year)         | 67.8 (13.1)        | 54.3 (12.3)     | < 0.01    | 67.4 (13.2)        | 53.6 (12.3)     | < 0.01    | 0.58       |
| Women              | 227 (34.7)         | 59 (38.8)       | 0.39      | 219 (34.5)         | 64 (35.8)       | 0.82      | 0.65       |
| History of CVD     | 284 (43.4)         | 32 (21.1)       | < 0.01    | 260 (40.9)         | 35 (19.6)       | < 0.01    | 0.84       |
| Diabetes mellitus  | 176 (27.5)         | 24 (16.1)       | < 0.01    | 163 (26.0)         | 33 (18.4)       | 0.05      | 0.68       |
| Dialysis vintage (months)* | 27.0 (12.0–55.0) | 25.5 (11.8–48.0) | 0.23    | 26.0 (12.0–56.0) | 24.0 (12.0–42.0) | 0.16    | 0.69       |
| Systolic BP (mmHg) | 141.7 (24.3)       | 141.6 (21.5)    | 0.96      | 141.0 (23.9)       | 141.6 (21.4)    | 0.79      | 0.98       |
| Diastolic BP (mmHg)| 72.4 (14.8)        | 77.0 (11.6)     | < 0.01    | 72.6 (13.5)        | 78.8 (12.9)     | < 0.01    | 0.18       |
| Vascular access, AVF | 520 (79.5)       | 140 (92.1)      | < 0.01    | 526 (82.8)         | 160 (89.4)      | 0.04      | 0.51       |
| Duration of a dialysis session (min) | 230.7 (22.0) | 232.1 (20.6)    | 0.45     | 230.7 (20.8)       | 234.2 (21.3)    | 0.05      | 0.38       |
| Blood flow (ml/min)* | 350 (300–400)    | 350 (300–400)   | 0.82      | 350 (320–400)      | 350 (300–400)   | 0.35      | 0.27       |
| Dialysis single pool Kt/V | 1.52 (0.30)     | 1.53 (0.31)     | 0.92      | 1.6 (0.3)          | 1.5 (0.3)       | 0.30      | 0.83       |
| Hemoglobin (g/dL)  | 11.9 (1.4)         | 11.9 (1.2)      | 0.41      | 11.9 (1.4)         | 12.2 (1.3)      | < 0.01    | 0.07       |
| Phosphorus (mg/dL) | 4.8 (1.5)          | 5.0 (1.4)       | 0.14      | 4.8 (1.5)          | 5.2 (1.5)       | < 0.01    | 0.08       |
| B2 microglobulin (mg/L)* | 25.9 (19.8–36.2) | 28.5 (20.9–38.1) | 0.43    | 25.8 (18.8–34.9)  | 26.7 (18.7–34.3) | 0.88    | 0.19       |
| BMI after dialysis (kg/m²) | 25.4 (4.6)         | 24.6 (4.0)      | 0.06     | 25.1 (5.0)         | 25.1 (4.0)      | 0.97      | 0.25       |
| Albumin (g/dL)     | 4.0 (0.4)          | 4.2 (0.4)       | < 0.01    | 4.1 (0.4)          | 4.2 (0.4)       | < 0.01    | 0.61       |
| C-reactive protein (mg/L)* | 5.7 (3.4–12.8) | 4.9 (1.6–8.4)    | < 0.01   | 6.2 (3.1–14.1)     | 4.9 (1.6–9.9)   | < 0.01    | 0.51       |
| Predialysis creatinine (mg/dL) | 8.7 (2.7)        | 9.7 (2.8)       | < 0.01    | 8.4 (2.7)          | 9.9 (2.7)       | < 0.01    | 0.56       |
| Cholesterol (mmol/L) | 3.7 (1.0)         | 3.7 (1.2)       | 0.90      | 3.7 (0.9)          | 3.6 (0.9)       | 0.48      | 0.59       |
| Body Surface Area (m²) | 1.8 (0.2)         | 1.8 (0.2)       | 0.62      | 1.8 (0.2)          | 1.8 (0.2)       | 0.42      | 0.96       |
| Convection volume (L)* | –               | –               | –         | 22.8 (19.8–25.4)   | 22.9 (20–25.9)  | 0.40      | –          |

Values are n (%) for categorical variables, and mean (standard deviation) or *median (Q1-Q3) for continuous variables

* p-values indicates differences between the patients who did not receive transplantation versus those who did in, respectively, the HD and HDF arm

** p-values indicates differences between the patients who received transplantation in the HD arm versus the patients who received transplantation in the HDF arm

*** p-values indicates differences between the patients who received transplantation in the HDF arm versus the patients who received transplantation in the HD arm

CVD cardiovascular disease, BP blood pressure, AVF arteriovenous fistula, BMI body mass index
that patients treated by HDF received fewer kidney transplants compared with HD patients [29].

We were unable to examine post-transplantation patient and graft survival due a limited follow-up after transplantation (median time of follow-up post-transplantation: 24 months), limited number of post-transplantation events, and differences in transplantation rates between countries. The different effects between HD and HDF in terms of oxidative stress, immune function, and hemodynamic treatment tolerance, on the success of kidney transplantation remain an interesting area of research. There are multiple studies that have compared post-transplantation outcomes [30–41]. Yet, these studies all compared the post-transplantation outcomes for patients who underwent pre-transplantation treatment with PD versus HD. Therefore, it remains unclear as to whether the choice of pre-dialysis treatment modality affects post-transplantation survival, and future research is required to elucidate this further.

The strengths of our study are that we analysed IPD from the largest available set of RCTs and made appropriate adjustment for measured and unmeasured confounders. Consequently, we produced the most reliable evidence on whether the likelihood of receiving a kidney transplant differed between HD and HDF for patients with CKD5D. However, our study is subject to some limitations. The four trials were not primarily designed to study the likelihood of patients receiving kidney transplants, since the primary end-point was mortality and differences between trials in terms of study design and methodology, and in- and exclusion criteria of patients remain. Therefore, we do not draw any causal conclusions in terms of renal transplantation and dialysis modalities. We explored these clinical differences in a wide range of subgroup analyses, which illustrated that our findings were robust for all explored factors, including patient characteristics and comorbidities. This might be limited by the fact that our study population consisted largely of European Caucasian patients. Finally, the average follow-up duration in the studies in our IPD dataset was approximately 2.5 years [12], while the average waiting time for kidney transplantation in Europe might be longer [42, 43], and the median waiting time in US is 3.6 years [3]. Potentially, a greater number of patients could have received a kidney transplant after the end of our data collection, however, it is unlikely that this would influence our findings given that we have not found any difference in the likelihood of undergoing kidney transplantation between the two treatment modalities in any subgroup or the level of convection volume delivered during treatment sessions.

In conclusion, online HDF, compared with conventional HD, does not affect the likelihood of receiving a kidney transplant. This finding holds across a variety of important clinical subgroups and is not affected by the level of convection volume delivered during HDF treatment sessions.

### Table 2 Hazard ratio and 95% confidence intervals for receiving transplantation comparing HDF versus HD, overall and in predefined strata

|                         | Transplantation | P-value for interaction |
|-------------------------|----------------|-------------------------|
|                         | Overall        |                         |
| Sex                     |                |                         |
| Male                    | 1.07 (0.86–1.33) | –                       |
| Female                  | 1.01 (0.77–1.33) |                         |
| Age                     |                |                         |
| < 60 years              | 1.27 (0.96–1.68) | 0.42                    |
| ≥ 60 years              | 0.87 (0.62–1.23) | 0.09                    |
| Diabetes                |                |                         |
| No                      | 1.05 (0.83–1.34) |                         |
| Yes                     | 1.26 (0.74–2.13) | 0.54                    |
| History of CVD          |                |                         |
| No                      | 1.17 (0.92–1.50) |                         |
| Yes                     | 0.88 (0.55–1.43) | 0.30                    |
| Albumine (g/dL)         |                |                         |
| < 4                     | 1.15 (0.72–1.64) |                         |
| ≥ 4                     | 1.06 (0.82–1.38) | 0.92                    |
| Creatinine (mg/dl), predialysis | |                         |
| < 8                     | 0.91 (0.60–1.37) |                         |
| ≥ 8                     | 1.14 (0.87–1.47) | 0.37                    |
| Dialysis vintage        |                |                         |
| < 30 months             | 1.13 (0.85–1.50) |                         |
| ≥ 30 months             | 1.00 (0.71–1.40) | 0.58                    |
| Fistula                 |                |                         |
| No                      | 1.44 (0.70–2.97) |                         |
| Yes                     | 1.04 (0.83–1.31) | 0.40                    |

Table 2 Hazard ratio and 95% confidence intervals for receiving transplantation comparing HDF versus HD, overall and in predefined strata

### Table 3 Hazard ratio and 95% confidence intervals for transplantation by delivered BSA-standardized convection volume in litres per 1.73m² per treatment with standard haemodialysis as a reference

|                  | HD | HDF convection volume |
|------------------|----|-----------------------|
|                  | <19| 19–23 | >23 |
| Total patients   | 806| 211  | 230 | 359 |
| Number of renal transplants | 152 (18.9%)| 49 (23.2%) | 52 (22.6%) | 77 (21.4%) |
| Crude ref.       | 1.15 (0.82–1.61) | 1.02 (0.75–1.41) | 1.06 (0.80–1.40) |
| Adjusted* ref.   | 1.35 (0.95–1.90) | 1.15 (0.82–1.60) | 1.06 (0.79–1.41) |

*Adjusted for age, sex, albumin, creatinine, history of cardiovascular diseases, and diabetes. Values are hazard ratios and 95% confidence intervals (e.g. guidelines) of the countries of the included studies. Given the pragmatic nature of all trials included, this does not differ from actual clinical practice.

Most of the previous studies on the likelihood of receiving a kidney transplant have focussed on the comparison of HD versus PD, and the role of HDF in access to transplantation has rarely been investigated. One meta-analysis of Wang et al., including six studies with 2727 patients, reported a borderline significant increase (RR: 1.20, 95% CI: 1.00–1.44) in the likelihood of receiving a kidney transplant among patients treated with HDF compared to those patients treated with HD [10]. However, the limitations of this review are aggregated data, without subgroup analyses. These findings are contradicted by an observational registry study, including 28, 407 patients (median follow-up: 1.95 years), that found
### Appendix 1

**Table 4** Baseline characteristics of the patients who received transplantation during follow-up stratified by study

|                | CONTRAST | ESHOL | French study | Turkish study | p-value |
|----------------|----------|-------|--------------|---------------|---------|
| N (n, %)       | 151 (21.1) | 180 (19.6) | 7 (1.8) | 17 (2.2) |         |
| Age (year)     | 53.4 (12.3) | 54.4 (12.3) | 67.7 (2.7) | 44.5 (12.9) | < 0.001 |
| Female sex     | 63 (41.7) | 60 (33.3) | 3 (42.9) | 7 (41.2) | 0.446   |
| History of CVD | 33 (21.9) | 34 (18.9) | 3 (33.3) | 7 (41.2) | 0.364   |
| Diabetes       | 30 (20.3) | 27 (15.0) | 1 (16.7) | 5 (29.4) | 0.372   |
| Dialysis vintage (months)* | 26.0 (14.0–44.0) | 23.0 (10.8–44.3) | 32.3 (21.7–48.7) | 55.8 (27.8–75.0) | 0.013   |
| Systolic BP (mmHg) | 147.6 (21.5) | 136.5 (20.0) | 141.7 (24.6) | 125.9 (11.0) | < 0.001 |
| Diastolic BP (mmHg) | 80.0 (10.7) | 76.3 (13.3) | 72.5 (5.8) | 74.7 (7.8) | 0.017   |
| Vascular access, AVF | 130 (86.1) | 170 (94.4) | 3 (42.9) | 15 (88.2) | < 0.001 |
| Duration of a dialysis session (min) | 227.6 (22.1) | 237.8 (18.9) | 225.0 (36.7) | 237.5 (3.6) | < 0.001 |
| Blood flow (ml/min)* | 300 (275–325) | 400 (350–400) | 310 (300–335) | 309.2 (297.4–346.3) | < 0.001 |
| Dialysis single pool Kt/V | 1.4 (0.2) | 1.7 (0.3) | 1.7 (0.2) | 1.4 (0.3) | < 0.001 |
| Hemoglobin (g/dL) | 11.9 (1.1) | 12.2 (1.3) | 11.0 (1.4) | 11.8 (1.3) | 0.013   |
| Phosphorus (mg/dL) | 5.2 (1.5) | 5.0 (1.4) | 4.5 (1.9) | 4.9 (1.1) | 0.291   |
| B-2 microglobulin (mg/L)* | 32.3 (24.6–40.7) | 20.9 (16.3–26.9) | 23.0 (21.0–27.2) | 26.2 (23.9–28.3) | < 0.001 |
| BMI after dialysis (kg/m²) | 24.9 (3.7) | 24.8 (4.2) | 24.1 (1.6) | 24.4 (5.0) | 0.934   |
| Albumin (g/dL) | 4.1 (0.4) | 4.2 (0.4) | 4.0 (0.4) | 4.0 (0.3) | 0.108   |
| C-reactive protein (mg/L)* | 2.3 (0.9–6.8) | 5.0 (2.6–10.4) | 1.9 (0.9–6.6) | 1.0 (0.2–1.3) | < 0.001 |
| Predialysis creatinine (mg/dL) | 11.1 (2.6) | 8.6 (2.4) | 7.3 (2.4) | 9.1 (2.2) | < 0.001 |
| Cholesterol (mmol/L) | 3.7 (1.1) | – | 4.7 (1.2) | 4.5 (1.1) | 0.001   |
| Body Surface Area (m²) | 1.9 (0.2) | 1.8 (0.2) | 1.7 (0.2) | 1.7 (0.2) | < 0.001 |

Values are n (%) for categorical variables, and mean (standard deviation) or *median (Q1-Q3) for continuous variables

CVD cardiovascular disease, BP blood pressure, AVF arteriovenous fistula, BMI body mass index

### Appendix 2

**Table 5** Hazard ratio and 95% confidence intervals of transplantation comparing HDF versus. HD stratified by study

|                | CONTRAST Hazard ratio (95%-CI) | p-value for interaction | ESHOL Hazard ratio (95%-CI) | p-value for interaction |
|----------------|--------------------------------|-------------------------|-----------------------------|-------------------------|
| Overall        | 1.06 (0.77–1.45)                | –                       | 1.19 (0.88–1.61)            | –                       |
| Sex            |                                 |                         |                             |                         |
| Male           | 1.00 (0.66–1.52)                | –                       | 1.09 (0.75–1.58)            |                         |
| Female         | 1.14 (0.69–1.86)                | 0.70                    | 1.43 (0.85–2.40)            | 0.40                    |
| Age            |                                 |                         |                             |                         |
| < 60 years     | 1.47 (0.98–2.19)                |                         | 1.27 (0.85–1.88)            |                         |
| ≥ 60 years     | 0.65 (0.38–1.11)                | 0.02                    | 1.08 (0.68–1.72)            | 0.61                    |
| Diabetes       |                                 |                         |                             |                         |
| No             | 1.02 (0.71–1.46)                |                         | 1.16 (0.83–1.61)            |                         |
| Yes            | 1.42 (0.68–2.99)                | 0.43                    | 1.29 (0.60–2.78)            | 0.80                    |
| History of CVD |                                 |                         |                             |                         |
| No             | 1.16 (0.81–1.67)                |                         | 1.29 (0.92–1.80)            |                         |
| Yes            | 0.80 (0.40–1.59)                | 0.35                    | 0.97 (0.48–1.94)            | 0.46                    |
| Albumin        |                                 |                         |                             |                         |
| < 4 g/dL       | 0.98 (0.57–1.69)                |                         | 1.56 (0.81–3.02)            |                         |
| ≥ 4 g/dL       | 1.07 (0.72–1.60)                | 0.80                    | 1.12 (0.79–1.59)            | 0.38                    |
| Dialysis vintage |                                 |                         |                             |                         |
| < 30 months    | 1.28 (0.83–1.98)                |                         | 1.07 (0.74–1.55)            |                         |
| ≥ 30 months    | 0.85 (0.52–1.38)                | 0.21                    | 1.47 (0.87–2.47)            | 0.33                    |
| Fistula        |                                 |                         |                             |                         |
| No             | 1.65 (0.66–4.08)                |                         | 1.58 (0.45–5.48)            |                         |
| Yes            | 1.00 (0.71–1.41)                | 0.32                    | 1.19 (0.87–1.63)            | 0.67                    |
Appendix 3

List of study investigators

The HDF Pooling project group comprises of all principal investigators of the individual studies that participate in the HDF Pooling project.

ESHOL investigators: Francisco Maduell, Francesc Moreoso, Mercedes Pons, Rosa Ramos, Josep Mora-Macía, Jordi Carreras, Jordi Soler, Ferran Torres, Josep M. Campistol, and Alberto Martínez-Castelao M. Pons, B. Insensé, C. Perez, and T. Feliz (CETIRSA, Barcelona); R. Ramos, M. Barbeta, and C. Soto (Hospital San Antonio Abad, Vilanova i la Geltrú); J. Mora, A. Juan, and O. Ibrik (Fresenius Medical Care, Granollers); A. Foraster and J. Carreras (DiaverumBax Llobregat, Hospitalitaet); F. Moreoso, J. Nin, and A. Fernández (Fresenius Medical Care, Hospitalitaet); J. Soler, M. Arruche, C. Sánchez, and J. Vidiella (Fresenius Medical Care, Reus); F. Barbosa, M. Chiné, and S. Hurtado (Fresenius Medical Care Diagonal, Barcelona); J. Llibre, A. Ruiz, M. Serra, and T. Poyuelo (CETIRSA, Terrassa); F. Maduell, M. Carrera, N. Fontseré, M. Arias, and Josep M. Campistol (Hospital Clinic, Barcelona); A. Merín and L. Ribera (Fresenius Medical Care Julio Verne, Barcelona); J.M. Galceran, J. Módel, E. Moliner, and A. Ramírez (Fundació Althaia, Manresa); J. Aguilerà and M. Alvarez (Hospital Santa Tecla, Tarragona); B. de la Torre and M. Molera (Diaverum Bonanova, Barcelona); J. Casellas and G. Martín (Diaverum IHB, Barcelona); E. Andres and E. Coll (Fundació Puigvert, Barcelona); M. Valles and C. Martínez (Hospital Josep Trueta, Girona); E. Castellote (Hospital General, Vic); J.M. Casals, J. Gabàs, and M. Romero (Diaverum, Mataró); A. Martinez-Castelao and X. Fulladosa (Hospital Universitari Bellvitge, Hospitalitaet); M. Ramirez-Arellano and M. Fulquet (Hospital de Terrassa); A. Pelegrí, M. el Manouari, and N. Ramos (Diaverum Verge de Montserrat, Santa Coloma); J. Bartolomé (Centre Secretari Coloma, Barcelona); R. Sans (Hospital de Figueres); E. Fernández and F. Sarró (Hospital Arnau de Vilanova, Lleida); T. Compte (Hospital Santa Creu, Tortosa); F. Marco and R. Mauri (Diaverum Nephros, Barcelona); and J. Bromsons (Clinica Girona), J.A. Arnaiz, H. Beleta, and A. Pejenaute (UASP Farmacología Clínica, Hospital Clinic Barcelona), F. Torres, J. Rios, and J. Lara (Biostatistics Unit, School of Medicine, Universitat Autònoma de Barcelona).

CONTRAST investigators: P.J. Blankestijn, M.P.C. Grooteman, M.J.Nubé, P.M. ter Wee, M.L. Bots; M.A. van den Dorpel, Canada; Georges-L. Dumont Regional Hospital, Moncton: M. Dorval; CHUM St. Luc Hospital, Montréal: R. Lévesque. The Netherlands: Academic Medical Center, Amsterdam: M.G. Koopman; Catharina Hospital, Eindhoven: C.J.A.M. Konings; Dialysis Clinic Noord, Beilen: W.P. Haanstra; Dialysis Centers, Utrecht: M. Kooistra and B. van Jaarsveld; Franciscus Hospital, Roosendaal: T. Noordzij; Gelderse Vallei Hospital, Ede: G.W. Feith; Groene Hart Hospital, Gouda: H.G. Peltenburg; Haga Hospital, The Hague: M. van Buren; Isala Clinics, Zwolle: J.J.G. Offerman; Jeroen Bosch Hospital, Hertogenbosch: E.K. Hoogeveen; Maasstad Hospital, Sittard: F. De Heer; Maasstad Hospital, Rotterdam: P.J. van de Ven; Martini Hospital, Groningen: T.K. Kremer Hovinga; Medical Center Alkmaar: W.A. Bax; Onze Lieve Vrouwe Gasthuis, Amsterdam: J.O. Groeneveld; Oosterschelde Hospital, Goes: A.T.J. Lavrijssen; Rijnland Hospital, Leiderdorp: A.M. Chrander; Van der Meer; Rijnstate Hospital, Arnhem: L.J.M. Rechert; Slingeland Hospital, Doetinchem: J. Huussen; St. Elisabeth Hospital, Tilburg: P.L. Rensma; St. Franciscus Gasthuis, Rotterdam: Y. Schrama; University Medical Center St. Radboud, Nijmegen: H.W. van Hamersvelt; University Medical Center Utrecht, Utrecht: W.H. Boer; VieCuri Medical Center, Venlo: W.H. van Kuijk; VU University Medical Center, Amsterdam: M.G. Vervloet; Zeeuws-Vlaanderen Hospital, Terneuzen: J.M.P.M.J. Wauters. Norway: Haukeland University Hospital, Bergen: I. Sekse.

Turkish HDF Study investigators: Ercan Ok, Gulay Asci, Huseyin Toz, Ebru Sevinc Ok, Fatih Kircelli, Mumtaz Yilmaz, Ender Hür, Metem Sezis Demirci, Cenk Demirci, Soner Duman, Ali Basci, Siddig Momin Adam, Ismet Onder Isik, Murat Zengin, Gultekin Suleymanlar, Mehmet Emir Yilmaz and Mehmet Ozkahya Pinar Ergin, Alpert Sagdic, Erkan Kayali, Can Boydak, Taskin Colak, Sihli Caliskan, Hakan Kaplan, Hasibe Ulas, Sait Kirbiyik, Hakan Berkutas and Necati Dilbaz.

French HDF Study investigators: Bernard Canaud, Jean-Paul Cristol, Marion Morena, Hélène Leray-Moragues, Léa Chenine, Marine-Christine Picot, Audrey Jaussent, Claire Belloc, Mélodie Larguigue (University Hospital Center, Montpellier), Lotfi Chalabi (AIDER, Montpellier), Alain Debure, Messaoud Ouzila, Jean-Jacques Lefevre (ATS, St Denis), Damien Thibaudin, Hesham Mohey, Christian Broyet, Aïda Aliani, (University Hospital Center, Saint Etienne), Marie-Odile Serveau, Laure Patrier (University Hospital Center, Nimes), François Maurice, Jean-Pierre Rivory (CHL, Castelnau le Lez), Philippe Nicoud (La Vallée Blanche center, Chamonix), Claude Durand, Michel Normand (Saint Martin polyclinic, Pessac), Bruno Seigneu- ric (University Hospital Center, Toulouse), Eric Magnant (Centre Hémodialyse Provence, Aix en Provence), Lynda Azzouz (Artic 42, St Priest en Jarez), Mohamed Sharifil Islam, Sandor Vido (University Hospital Center, Nice), Hilaire Nzyimanana, Danièle Simonin (ECHO Michel Ange center, Le Mans), Yamina Azymah, Ibrahim Farah, Jean-Philippe Coindre (Hospital center, Le Mans), Olivier Puyoo, Marie-Hélène Chabannier, Richard Ibos, Fabienne Rouleau (Centre Néphrologique d’Occitanie, Muret), Carlos Vela, Josiane Joule (Hospital center, Perpignan), François Combarnous (Tonkin clinic, Villeurbanne), Cécile Turc-Baron, Francis Ducret, Philippe Pointet, Isabelle
the International Society of Nephrology/ Baxter Extramural

restrict grants from Fresenius Medical Care, Netherlands,

was supported by a grant from the Dutch Kidney Found-

the Catalan Society of Nephrology. The CONTRAST study

grant. The study was performed in Fresenius Medical

Nephrology and Dialysis Institute with an unrestricted

for any part of or activity related to the present analysis.

EDTA, http://era-edta.org/eudial/European_Dialysis_-

European Dialysis Transplant Association (ERA-

ficial working group of the European Renal Association

supported by the EuDial working group. EuDial is an of-

work as a whole. The HDF Pooling project group comprises of all principal

investigators of the individual studies that participate in the HDF Pooling

project (Appendix 3). The authors read and approved the final manuscript.

Funding details are listed in Appendix 4 . RWMV, PJB, and MLB are funded by

the CONVINCE study (European Union’s Horizon 2020 research and

novation programme under grant agreement No 754803).

Requests for access to the data of the HDF pooling project can be directed

the corresponding author. Requests will be handled by the executive

committee of the HDF pooling project.

Ethics approval and consent to participate

All patients provided necessary informed consent to participate in the

present study and ethical approval was obtained in the individual studies. All

methods were carried out in accordance with relevant guidelines and

regulations. The CONTRAST was approved by both a central medical ethics

review board and local ethics committees of the participating hospitals. The

local ethics committee of Ege University Izmir, Turkey, approved the study

protocol of the Turkish study. The ESHOL study was approved by the ethics

committee of each participating centre. The French study was approved by

the Montpellier University Hospital ethics committee.

Consent for publication

Not applicable.

Competing interests

None declared.

Author details

1Department of Nephrology and Hypertension, University Medical Center

Utrecht, Utrecht, the Netherlands. 2Julius Center for Health Sciences and

Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht,

the Netherlands. 3Wai-ping Law, Renal unit, Department of medicine, Queen

Elizabeth Hospital, Hong Kong, PR China. 4The George Institute for Global

Health, School of Public Health, Imperial College, London, UK. 5The George

Institute for Global Health, University of New South Wales, Sydney, Australia.

6Global Medical Office, Fresenius Medical Care Deutschl and, Bad Homburg,

Germany. 7Montpellier University, School of Medicine, Montpellier, France.

8University College London, Centre for Nephrology, Royal Free Hospital,

London, UK. 9Department of Nephrology and Amsterdam Cardiovascular

Sciences (ACS), Amsterdam University Medical Centers, VU University,

Amsterdam, The Netherlands. 10Division of Nephrology, Ege University

School of Medicine, Izmir, Turkey. 11Department of Nephrology, Alessandro

Manzoni Hospital, past director, Lecco, Italy. 12Nephrology Department,

Hospital Clinic, Barcelona, Spain. 13PhyMedExp, University of Montpellier, INSE

RM, CNRS, Biochemistry/Hormonology department, University Hospital

Center of Montpellier, Montpellier, France. 14Biostatistics Unit, School of

Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 15Medical

Statistics core facility, IDIBAPS, Hospital Clinic, Barcelona, Spain. 16Department

of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.

Rey (Hospital center, Annecy), Jacky Potier (Hospital center, Cherbour), Jean- Christophe Bendini, Franck Perrin (St Georges clinic, Nice), Kristian Kunz (University Hospital Center, Strasbourg), Gaëlle Lefrançois, Angélique Colin, Sophie Parah, Irina Dancea, Stéphanie Coupel, Angelo Testa (ECHO center, Rezé), Philippe Brunet, Gaëtan Lebrun, Dominique Jaubert (University Hospital Center AP-HM, Marseille), Catherine Delcroix, Frédéric Lavainne, Anne Lefebvre (University Hospital Center, Nantes), Marie-Paule Guillodo, Dominique Le Grignou (AUB, Brest), Assia Djema (Hospital center, Cholet), Mehadj Maaz, Sylvie Chiron (Hospital center, Colmar), Maxime Hoffmann, Pascale Depraetere (Louvière clinic, Lille), Atman Haddj-Elmarabet, Véronique Joyeux (University Hospital Center, Rennes), Dominique Fleury, Laurence Vigneaud, Vincent Lemaître (Hospital center, Valenciennes), Didier Aguilera, Abdallah Guerraoui (Hospital center, Vichy), Alain Cremault, Achor Laradi, Francois Babinet (ECHO Pole Santé Sud center, Le Mans).

The writing executive committee, whose membership did not include representatives of the financial contributors, has final responsibility for the interpretation of the data, the preparation of the manuscript and the decision to submit for publication. The executive committee vouches for the validity and completeness of the reported data.

Appendix 4

Funding

The HDF Pooling project was designed, conducted, and analysed independently of the financial contributors of the individual studies as listed below. Study data were collected and retained by the investigators and were not available for the financial contributors of the individual studies. SAEP and the meetings of the representatives of the combined authors of the four studies were financially supported by the EuDial working group. EuDial is an official working group of the European Renal Association – European Dialysis Transplant Association (ERA-EDTA, http://era-edta.org/eudial/European_Dialysis_ Working_Group.html. No industry funding was received for any part of or activity related to the present analysis.

The Turkish HDF study was supported by European Nephrology and Dialysis Institute with an unrestricted grant. The study was performed in Fresenius Medical Care haemodialysis clinics in Turkey. ESHOL was supported by The Catalan Society of Nephrology and by grants from Fresenius Medical Care and Gambro through the Catalan Society of Nephrology. The CONTRAST study was supported by a grant from the Dutch Kidney Foundation (Nierstichting Nederland Grant C02.2019), and unrestricted grants from Fresenius Medical Care, Netherlands, and Gambro Lundia AB, Sweden. Additional support was received from the Dr. E.E. Twiss Fund, Roche Netherlands, the International Society of Nephrology/ Baxter Extramural Grant Program, and the Netherlands Organization for Health Research and Development (ZONMW Grant 170, 882,802). The French HDF study was supported by a national grant from the Health Ministry (Programme Hospitalier de Recherche Clinique, PHRC) as a mean to improve care and outcome of elderly chronic disease patients.

Acknowledgements

Not applicable.

Authors’ contributions

RWMV, PJB, and MLB drafted the report. RWMV and ML did the analyses. All authors contributed to the interpretation of the data, the preparation of the manuscript, and the decision to submit for publication. RWMV, MLB, and PJB vouch for the validity of the study and are responsible for the integrity of the work as a whole. The HDF Pooling project group comprises of all principal investigators of the individual studies that participate in the HDF Pooling project (Appendix 3). The authors read and approved the final manuscript.

Funding

Funding details are listed in Appendix 4 . RWMV, PJB, and MLB are funded by the CONVINCE study (European Union’s Horizon 2020 research and innovation programme under grant agreement No 754803).

Availability of data and materials

Requests for access to the data of the HDF pooling project can be directed to the corresponding author. Requests will be handled by the executive committee of the HDF pooling project.

Ethics approval and consent to participate

All patients provided necessary informed consent to participate in the present study and ethical approval was obtained in the individual studies. All methods were carried out in accordance with relevant guidelines and regulations. The CONTRAST was approved by both a central medical ethics review board and local ethics committees of the participating hospitals. The local ethics committee of Ege University Izmir, Turkey, approved the study protocol of the Turkish study. The ESHOL study was approved by the ethics committee of each participating centre. The French study was approved by the Montpellier University Hospital ethics committee.

Consent for publication

Not applicable.

Competing interests

None declared.

Author details

1Department of Nephrology and Hypertension, University Medical Center

Utrecht, Utrecht, the Netherlands. 2Julius Center for Health Sciences and

Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht,

the Netherlands. 3Wai-ping Law, Renal unit, Department of medicine, Queen

Elizabeth Hospital, Hong Kong, PR China. 4The George Institute for Global

Health, School of Public Health, Imperial College, London, UK. 5The George

Institute for Global Health, University of New South Wales, Sydney, Australia.

6Global Medical Office, Fresenius Medical Care Deutschl and, Bad Homburg,

Germany. 7Montpellier University, School of Medicine, Montpellier, France.

8University College London, Centre for Nephrology, Royal Free Hospital,

London, UK. 9Department of Nephrology and Amsterdam Cardiovascular

Sciences (ACS), Amsterdam University Medical Centers, VU University,

Amsterdam, The Netherlands. 10Division of Nephrology, Ege University

School of Medicine, Izmir, Turkey. 11Department of Nephrology, Alessandro

Manzoni Hospital, past director, Lecco, Italy. 12Nephrology Department,

Hospital Clinic, Barcelona, Spain. 13PhyMedExp, University of Montpellier, INSE

RM, CNRS, Biochemistry/Hormonology department, University Hospital

Center of Montpellier, Montpellier, France. 14Biostatistics Unit, School of

Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 15Medical

Statistics core facility, IDIBAPS, Hospital Clinic, Barcelona, Spain. 16Department

of Epidemiology, Johns Hopkins University, Baltimore, MD, USA.
References

1. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095–128.

2. Wolfe RA, LaPorte FB, Rodgers AM, Roys EC, Fant G, Leightman AB. Developing organ offer and acceptance measures when “good” organs are turned down. Am J Transplant. 2007;7(5 Pt 2):1404–11.

3. United States Renal Data System. 2019 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2019.

4. Yingman-Uhlin P, Fogelberg A, Uhnin F. Life in standby: hemodialysis patients’ experiences of waiting for kidney transplantation. J Clin Nurs. 2016;25(1–2):192–8.

5. Qiao B, Liu L, Liu J, Xie J. A study on the attitude toward kidney transplantation and factors among hemodialysis patients in China. Transplant Proc. 2016;48(8):2601–7.

6. Koons B, Smetzer SC. The patient experience of waiting on the deceased donor kidney transplant list while receiving Dialysis. Nephrol Nurs J. 2018;45(4):349–55.

7. Snyder JJ, Kasikie BL, Gilberton DT, Collins AJ. A comparison of transplant outcomes in peritoneal and hemodialysis patients. Kidney Int. 2002;62(4):1423–30.

8. Chalem Y, Ryckelynck JP, Tuppin P, et al. Access to, and outcome of, renal transplantation according to treatment modality of end-stage renal disease in France. Kidney Int. 2005;67(6):2448–53.

9. Mehrotra R, Chiu YY, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011;171(2):110–8.

10. Wang Y, Ninomiya T, Al-Kahwa A, et al. Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis. 2014;63(6):968–78.

11. Locatelli F, Ateti P, Andrulei S, et al. Hemofiltration and hemodiafiltration reduce intradialytic hypotension in ESRD. J Am Soc Nephrol. 2010;21(10):1798–807.

12. Peters SA, Bots ML, Canaud B, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant. 2016;31(6):978–84.

13. Bleyer AJ, Russel GB, Satko SG. Sudden and cardiac death rates in hemodialysis patients. Kidney Int. 1999;55(5):1553–6.

14. Bárón P, Divino Filho JC, Bergström J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis. 1997;29(4):565–73.

15. Conti G, Amore A, Chiesa M, et al. Procalcitonin as a marker of inflammation in hemodialysis. J Nephrol. 2005;18(3):282.

16. Stewart LA, Clarke M, Rovers M, et al. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRIS MA-IPD statement. JAMA. 2015;313(16):1657–65.

17. Sheu BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.

18. Grooteboom MP, van den Dorpel MA, Bots ML, et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol. 2012;23(10):1087–96.

19. Ok E, Asci G, Töz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF study. Nephrol Dial Transplant. 2013;28:192–202.

20. Maduell F, Moeso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol. 2013;24:487–97.

21. Morena M, Jaussent A, Chalabi L, et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly. Kidney Int. 2017;91(6):1495–509.

22. Tattersall JE, Ward RA; EU-DIAL group. Online haemodiafiltration definition, dose quantification and safety revisited. Nephrol Dial Transplant. 2013;28(3):542–50.

23. Nistor I, Palmer SC, Craig JC, et al. Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials. Am J Kidney Dis. 2014;63(6):654–67.

24. Mostovaya IM, Blankestijn PJ, Bots ML, et al. Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis. Semin Dial. 2014;27(2):119–27.

25. Canaud B, Bragg-Gresham JL, Marshall MR, et al. Mortality risk for patients receiving hemodiafiltration versus hemodialysis: European results from the DOPPS. Kidney Int. 2006;69(1):1207–93.

26. Bellien J, Fréquin-Bouilland C, Joannidès R, et al. High-efficiency on-line haemodiafiltration improves conduit artery endothelial function compared with high-flux hemodiafiltration in end-stage renal disease patients. Nephrol Dial Transplant. 2014;29(2):414–22.

27. Schiff H. Prospective randomized cross-over long-term comparison of online haemodiafiltration and ultraflute high-flux haemodialysis. Eur J Med Res. 2007;12(1):26–33.

28. The Global Observatory on Donatio and Transplantation (GODT). http://www.transplant-observatory.org/. Accessed on 21 October 2020.

29. Mercadal L, Franck JE, Metzger M, et al. Hemodiafiltration versus hemodialysis and survival in patients with ESRD: the French renal epidemiology and information network (REIN) registry. Am J Kidney Dis. 2016;68(2):247–55.

30. Vanholder R, Heering P, Loo AV, et al. Reduced incidence of acute renal graft failure in patients treated with peritoneal dialysis compared with hemodialysis. Am J Kidney Dis. 1999;33(3):934–40.

31. Bleyer AJ, Burkat JM, Russell GB, Adams PL. Dialysis modality and delayed graft function after cadaveric renal transplantation. J Am Soc Nephrol. 1999;10(1):154–9.

32. Van Biesen W, Vanholder R, Van Loo A, Van Der Vennet M, Lameire N. Peritoneal dialysis favorably influences early graft function after renal transplantation compared to hemodialysis. Transplantation. 2000;69(4):508–14.

33. Ojo AO, Hanson JA, Wolfe RA, et al. Dialysis modality and the risk of allograft thrombosis in adult renal transplant recipients. Kidney Int. 1999;55(1):192–60.

34. Vats AN, Donaldson L, Fine RN, Chavers BM. Peritransplant dialysis status and outcome of renal transplantation in north American children: a NAPRTCS study. North American pediatric renal transplant cooperative study. Transplantation. 2000;69(7):1414–9.

35. Molnar MZ, Mehrotra R, Duong U, et al. Dialysis modality and outcomes in kidney transplant recipients. Clin J Am Soc Nephrol. 2012;7(2):332–41.

36. Passalacqua JA, Wiland AM, Fink JC, Bartett ST, Evans DA, Keay S. Increased incidence of postoperative infections associated with peritoneal dialysis in renal transplant recipients. Transplantation. 1999;68(4):335–40.

37. Goldfarb-Rumyantzev AS, Hurdle JF, Scandling JD, Baird BC, Cheung AK. The role of pretransplantation renal transplantation therapy modality in kidney allograft and recipient survival. Am J Kidney Dis. 2005;46(3):337–49.

38. Yang Q, Zhao S, Chen W, et al. Influence of dialysis modality on renal transplant complications and outcomes. Clin Nephrol. 2000;57(2):162–8.

39. Reesende L, Guerra J, Santana A, Mil-Homens C, Abreu F, da Costa AG. Influence of dialysis duration and modality on kidney transplant outcomes. Transplant Proc. 2009;41(13):837–9.

40. Heikal I, Abderrahim E, Ben Hamida F, et al. The first year renal function as a predictor of long-term graft survival after kidney transplantation. Transplant Proc. 2009;41(4):669–50.

41. Binaut R, Hazzan M, Pruvot FR, Dracon M, Lelièvre G, Noël C. Comparative study of chronic ambulatory peritoneal dialysis versus hemodialysis patients after kidney transplantation: clinical and financial assessment. Transplant Proc. 1997;29(5):2428.

42. Pippias M, Stel VS, Kramer A, et al. Access to kidney transplantation in European adults aged 75–84 years and related outcomes: an analysis of the European renal association-European Dialysis and transplant association registry. Transpl Int. 2018;31(5):540–53.

43. Stel VS, Kramer R, Leivestad T, et al. Time trend in access to the waiting list and renal transplantation: a comparison of four European countries. Nephrol Dial Transplant. 2012;27(9):3621–31.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.